title: [THE INFLUENCE OF PROGENITOR NEURO- CELLS SUPERNATANT ON THE LYMPHO- CYTES CYTOTOXIC FUNCTION IN RATS WITH GLIOMA].
abstract: The impact of rat neurogenic progenitor cells supernatant (RPNS) on the cytotoxic function of lymphocytes in rats under conditions of physiological norm and experimentally modeled tumor (brain glioma strain 101.8) was studied. The research was carried out in animals with inoculated tumor without RPNS injection and with different regimes of RPNS injection (thrice repeated from 5th to 10th day after glioma inoculation as well as 1 week and 1 month before tumor inoculation). Comparison groups included rats without glioma who triple injected with RPNS; and intact animals (control). RPNS was received from suspension of neurogenic progenitor cells (NPC) of rat brain on 14th day of gestation and injected intraperitoneally (0,12 mg per animal). Cytotoxic function of lymphocytes of experimental rats was evaluated in MTT-colorimetric test with allogeneic glioma cells. RPNS administration increased the cytotoxic activity of lymphocytes in vitro tests with allogeneic tumor cells in intact animals (to 37-38%) as well as in rats with glioma (to 11-22%). Under the RPNS influence the life expectancy and median survival of tumor-bearing animals increased (an average of 3-4 days). RPNS input modes such as triple injection from 5th to 10th day after glioma inoculation and 1 week before inoculation were the most effective. Thus, indirect tumor-inhibiting effect under intraperitoneal. RPNS administration in rats with glioma is demonstrated, which is obviously due to increased efficiency of cytotoxic function of immune cells of animals with inoculated tumor under the influence of the factors produced by NPC.
authors.forename: L D
authors.initials: LD
authors.lastname: Liubich
authors.forename: N I
authors.initials: NI
authors.lastname: Lisyany
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D017077:Culture Media, Conditioned / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004334:Drug Administration Schedule; D005910:Glioma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D007155:Immunologic Factors / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D058953:Neural Stem Cells / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D061251:Primary Cell Culture; D051381:Rats; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D017077:Culture Media, Conditioned; D007155:Immunologic Factors